Limited Stage Small Cell Lung Cancer (LS-SCLC) | Norton Healthcare

Indication: Limited Stage Small Cell Lung Cancer (LS-SCLC)

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Treated with chemoradiation

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: NRG Oncology

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.